📊 XERS Key Takeaways
Is Xeris Biopharma Holdings, Inc. (XERS) a Good Investment?
Xeris demonstrates strong 43.7% revenue growth but faces critical fundamental vulnerabilities: net income is essentially flat (0% YoY) despite massive top-line gains, and an extreme debt-to-equity ratio of 16.10x threatens financial stability. The 0.2% net margin combined with 6.8% gross margin indicates the company is not capturing profitability from growth, while a $220.3M debt burden is unsustainable given weak earnings power and modest 3.5x interest coverage.
Why Buy Xeris Biopharma Holdings, Inc. Stock? XERS Key Strengths
- Robust 43.7% YoY revenue growth demonstrates strong market demand
- Positive free cash flow of $27.5M with 9.4% FCF margin shows cash generation capability
- Substantial cash position of $111.0M provides short-term financial flexibility and runway
- Low capital expenditure requirements ($1.1M) indicate asset-light business model
XERS Stock Risks: Xeris Biopharma Holdings, Inc. Investment Risks
- Extreme leverage with 16.10x debt-to-equity ratio threatens solvency in economic downturns
- Net profitability completely stalled (0% YoY growth) despite 43.7% revenue growth indicating margin compression or cost structure problems
- Dangerously low 0.2% net margin leaves no room for operational error or revenue disruption
- Weak 6.8% gross margin for pharma sector suggests low pricing power or unsustainable cost structure
- Interest coverage of 3.5x is concerning and vulnerable to interest rate increases or EBITDA deterioration
- Large disconnect between free cash flow and net income suggests earnings quality concerns
Key Metrics to Watch
- Gross margin trend - must expand to 15%+ to justify debt load
- Net income growth acceleration - profitability must scale with revenue growth
- Debt reduction or debt-to-equity ratio - must improve toward 5x or lower
- Operating cash conversion - sustainability of FCF relative to net income gap
- Interest coverage ratio - must remain above 4.0x minimum
Xeris Biopharma Holdings, Inc. (XERS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.19x current ratio provides a solid financial cushion.
XERS Profit Margin, ROE & Profitability Analysis
XERS vs Healthcare Sector: How Xeris Biopharma Holdings, Inc. Compares
How Xeris Biopharma Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Xeris Biopharma Holdings, Inc. Stock Overvalued? XERS Valuation Analysis 2026
Based on fundamental analysis, Xeris Biopharma Holdings, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Xeris Biopharma Holdings, Inc. Balance Sheet: XERS Debt, Cash & Liquidity
XERS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Xeris Biopharma Holdings, Inc.'s revenue has grown significantly by 492% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.45 indicates the company is currently unprofitable.
XERS Revenue Growth, EPS Growth & YoY Performance
XERS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $54.3M | $621.0K | $0.00 |
| Q2 2025 | $48.1M | -$1.9M | $-0.01 |
| Q1 2025 | $40.6M | -$9.2M | $-0.06 |
| Q3 2024 | $48.3M | -$12.2M | $-0.09 |
| Q2 2024 | $38.0M | -$15.0M | $-0.10 |
| Q3 2023 | $29.7M | -$12.2M | $-0.09 |
| Q3 2022 | $11.1M | -$18.4M | $-0.16 |
| Q2 2022 | $8.9M | -$18.4M | $-0.19 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Xeris Biopharma Holdings, Inc. Dividends, Buybacks & Capital Allocation
XERS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Xeris Biopharma Holdings, Inc. (CIK: 0001867096)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 3, 2026 | 4 | xslF345X06/wk-form4_1775252722.xml | View → |
| Apr 1, 2026 | 4 | xslF345X06/wk-form4_1775080462.xml | View → |
| Mar 16, 2026 | 4 | xslF345X05/wk-form4_1773699093.xml | View → |
| Mar 5, 2026 | 4 | xslF345X05/wk-form4_1772756306.xml | View → |
| Mar 4, 2026 | 4 | xslF345X05/wk-form4_1772663325.xml | View → |
❓ Frequently Asked Questions about XERS
What is the AI rating for XERS?
Xeris Biopharma Holdings, Inc. (XERS) has an AI rating of SELL with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are XERS's key strengths?
Claude: Robust 43.7% YoY revenue growth demonstrates strong market demand. Positive free cash flow of $27.5M with 9.4% FCF margin shows cash generation capability.
What are the risks of investing in XERS?
Claude: Extreme leverage with 16.10x debt-to-equity ratio threatens solvency in economic downturns. Net profitability completely stalled (0% YoY growth) despite 43.7% revenue growth indicating margin compression or cost structure problems.
What is XERS's revenue and growth?
Xeris Biopharma Holdings, Inc. reported revenue of $291.8M.
Does XERS pay dividends?
Xeris Biopharma Holdings, Inc. does not currently pay dividends.
Where can I find XERS SEC filings?
Official SEC filings for Xeris Biopharma Holdings, Inc. (CIK: 0001867096) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is XERS's EPS?
Xeris Biopharma Holdings, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is XERS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Xeris Biopharma Holdings, Inc. has a SELL rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is XERS stock overvalued or undervalued?
Valuation metrics for XERS: ROE of 4.0% (sector avg: 15%), net margin of 0.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy XERS stock in 2026?
Our dual AI analysis gives Xeris Biopharma Holdings, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is XERS's free cash flow?
Xeris Biopharma Holdings, Inc.'s operating cash flow is $28.6M, with capital expenditures of $1.1M. FCF margin is 9.4%.
How does XERS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 0.2% (avg: 12%), ROE 4.0% (avg: 15%), current ratio 2.19 (avg: 2).
Is Xeris Biopharma Holdings, Inc. carrying too much debt?
XERS has a debt-to-equity ratio of 16.10x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 2.19 suggests adequate short-term liquidity.